InvestorsHub Logo
Followers 13
Posts 1001
Boards Moderated 0
Alias Born 03/12/2009

Re: None

Friday, 10/10/2014 7:34:59 AM

Friday, October 10, 2014 7:34:59 AM

Post# of 20775
Clinical Trials Update – Jan 16, 2014

VP20629 – Safety and Pharmacology Study of VP 20629 in Adults With FA
This study is actively enrolling and looking for volunteers at all sites (UCLA to open soon).
This is a Phase 1 study which means it is designed to evaluate dosage and safety. It is designed in two
arms. The first arm is four groups of 8 individuals (32 individuals needed for the first arm) in which each
individual gets a single dose of the drug and is monitored for 3 days. The first cohort of 8 has been
completed, and they are now enrolling the second cohort of 8 individuals.

After the first arm is completed, there will be a second arm of three groups of 8 subjects (24 individuals
needed for the second arm) in which individuals will receive multiple doses of VP 20629 (300 mg, 600
mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7
days with a single morning dose on Day 8.
Participation in this study requires both outpatient and inpatient visits. Subjects in the first arm need to
stay at the hospital for 3 days, and subjects in the second arm need to stay for 10 days. Subjects who
participate in arm 1 may be eligible to participate in arm 2.

Specific information on inclusion and exclusion criteria is available at the study’s clinicaltrials.gov site:
www.clinicaltrials.gov/ct2/show/NCT01898884.

Please call or email a coordinator below to get more information about the study.
OPEN FOR ENROLLMENT
Children’s Hospital of Philadelphia, Philadelphia, PA
Principal Investigator: Dr. David Lynch
Coordinators: Lauren Seyer, Tel: (267) 426-9738; email: seyerl@email.chop.edu and Debbie Foerster
Tel: (267) 426-7584; email: foerster@email.chop.edu
CHOP study ad - www.curefa.org/_pdf/VP20629ClinicalTrial.pdf
Emory University, Atlanta, GA
Principal Investigator: Dr. George Wilmot
Coordinator: Rebecca McMurray, Tel: (404) 728-6427; email: rebecca.s.mcmurray@emory.edu
Emory study ad – www.curefa.org/_pdf/EmoryTrialVP20629.pdf
University of Iowa, Iowa City, IA
Principal Investigator: Dr. Kathy Mathews
Coordinator: Carrie Stephan, Tel: (319) 356-2673; email: carrie-stephan@uiowa.edu
University of South Florida, Tampa, FL
Principal Investigator: Dr. Theresa Zesiewicz
Coordinator: Dr. Kelly Sullivan, Tel: (813) 974-5909; email: kbarber@health.usf.edu
ENROLLMENT ANTICIPATED SOON
UCLA Medical Center, Los Angeles, CA
Principal Investigator: Dr. Susan Perlman
Coordinator: Brian Clemente, Tel: (310) 794-1225; email: bclemente@mednet.ucla.edu

www.curefa.org/_pdf/VP20629-ClinicalTrialUpdate.pdf

Things that are equal to the same thing are also equal to one another (Transitive property of equality). If equals are added to equals, then the wholes are equal. If equals are subtracted from equals, then the remainders are equal. Things that coincide wi

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.